Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06881251 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
A Phase 2 study of Dermatitis, Atopic, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 2
- Development phase
- 256
- Enrollment target
- 20
- Study locations
NCT06881251: Active Phase 2 study of Dermatitis, Atopic, sponsored by Janssen Research & Development.
NCT06881251 is a Phase 2 study of Dermatitis, Atopic that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 256 participants, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06881251, a Phase 2 study of Dermatitis, Atopic, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 256 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
Primary Outcome
EASI-75 response is defined as at least 75 percent (%) improvement in EASI total score. EASI-75 response is defined as at least 75% improvement from baseline in EASI total score. The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration/papulation, excoriation and lichenification on 4 anatomic regions of the body: head/neck, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with t
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
- DRUG JNJ-95475939
Study Locations (20)
Other
- CIPREC - Buenos Aires
- INAER - Investigación en Alergias y Enfermedades Respiratorias - Buenos Aires
- Instituto de Neumonologia y Dermatologia - Buenos Aires
- Derma Internacional S A - Buenos Aires
- Ceti - Centro de Estudos Em Terapias Inovadoras - Curitiba
- Hospital De Clinicas De Porto Alegre - Porto Alegre
- Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP - Ribeirão Preto
Texas
- Arlington Center for Dermatology - Arlington
- Center for Clinical Studies - Houston
- Progressive Clinical Research - San Antonio
California
- First OC Dermatology - Fountain Valley
- University of California Los Angeles - Division of Dermatology - Los Angeles
Indiana
- Dawes Fretzin Clinical Research Group LLC - Indianapolis
- Indiana Clinical Trial Center - Plainfield
Georgia
- Hamilton Research LLC - Alpharetta
Illinois
- DeNova Research - Chicago
North Dakota
- Red River Research Partners LLC - Fargo
Ohio
- Optima Research - Boardman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 256 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2026-03-26 |
| Phase | Phase 2 |
What the registry record for NCT06881251 still lists
NCT06881251 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Dermatitis, Atopic appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06881251 names 20 study sites across 10 states, led by Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06881251 about?
NCT06881251 is a clinical study titled "A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)". The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
What is the current status of trial NCT06881251?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 256 participants. The study started on 2025-02-26. Estimated completion is 2026-03-26.
What conditions does trial NCT06881251 study?
This clinical trial studies the following conditions: Dermatitis, Atopic.
What interventions are being tested in trial NCT06881251?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG), JNJ-95475939 (DRUG).
Who is sponsoring clinical trial NCT06881251?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06881251 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Indiana, North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06881251's enrollment target sits among peer trials
256 12th of 29 higher than 18 of 29 other Dermatitis, Atopic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dermatitis, Atopic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
COMPLETED · Phase 2
-
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02464696 · 256 participants · NA
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
- NCT03793062 · 256 participants
Genetic and Epigenetic Basis of Chronic Wounds
- NCT04322318 · 256 participants · Phase 2
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
- NCT04468360 · 256 participants · Phase 2
Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI